Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 18, 2011Journal of Thoracic and Cardiovascular SurgeryOpen Access

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with hypertrophic cardiomyopathy

Design

Guideline

Key result

Hypertrophic cardiomyopathy can feature systolic dysfunction (EF 50%) associated with left ventricular remodeling, cavity enlargement, wall thinning, and diffuse myocardial scarring.

Authors

BGBernard J. GershBMBarry J. MaronRBRobert O. Bonow

Discussion

Loading...

Member takes

Overview

Recognize end-stage HCM progression in practice; reinforces guideline inclusion of adverse remodeling phenotypes.

Structured PICO

P
Population
Patients with hypertrophic cardiomyopathy
I
Intervention
Guideline-directed diagnosis and treatment

This document serves as the 2011 ACCF/AHA executive summary for the clinical diagnosis and management of hypertrophic cardiomyopathy.

Cite This Study

Gersh et al. (2011) studied this question. Hypertrophic cardiomyopathy can feature systolic dysfunction (EF 50%) associated with left ventricular remodeling, cavity enlargement, wall thinning, and diffuse myocardial scarring.

synapsesocial.com/papers/6aaba214300de2807df777cdhttps://doi.org/10.1016/j.jtcvs.2011.10.019
View Full Paper
Ask AI
Bookmark
Share